Saturday, 27 June 2020 08:24

Anticoagulation news items. Week commencing 22nd June 2020

Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure – guidance (TA626)

National Institute for Health and Care Excellence
Avatrombopag is recommended as an option for treating severe thrombocytopenia (platelet count of <50,000/microlitre of blood) in adults with chronic liver disease having a planned invasive procedure.


Community pharmacy-based study of adherence to non-vitamin K antagonist oral anticoagulants

Belgian study (n=766) found a positive patient attitude towards DOAC therapy, with 21% reporting non-adherence according to the Medication Adherence Report Scale, and unintentional non-adherence being the most commonly reported reason (15.4%).



The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: